Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease

Journal of Experimental Medicine

Volumn 202, Issue 5, 2005, Pages 575-581

  Landau, Anne M ^a   Luk, Kelvin C ^b   Jones, Michelle Lee ^a   Siegrist Johnstone, Rosmarie ^a   Yoon, Kow Young ^a   Kouassi, Edouard ^d,e   Rymar, Vladimir V ^b   Dagher, Alain ^c   Sadikot, Abbas F ^b   Desbarats, Julie ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FAS ANTIGEN; FAS LIGAND; NEUROTOXIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MODEL; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; FEMALE; FUNCTIONAL PROTEOMICS; HYPOKINESIA; IMMUNE SYSTEM; IN VITRO STUDY; LYMPHOPROLIFERATIVE DISEASE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; MUTAGENESIS; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; STRIATONIGRAL DEGENERATION; TREMOR;

AGED; ANIMALS; ANTIGENS, CD95; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, MUTANT STRAINS; MIDDLE AGED; MPTP POISONING; NEURONS; PARKINSON DISEASE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 24344455580     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20050163     Document Type: Article

References (26)

1. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355-365.
2. Choi, C., and E.N. Benveniste. 2004. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res. Brain Res. Rev. 44:65-81.
3. Martin-Villalba, A., I. Herr, I. Jeremias, M. Hahne, R. Brandt, J. Vogel, J. Schenkel, T. Herdegen, and K.M. Debatin. 1999. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19:3809-3817.
4. Raoul, C., A.G. Estevez, H. Nishimune, D.W. Cleveland, O. deLapeyriere, C.E. Henderson, G. Haase, and B. Pettmann. 2002. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron. 35:1067-1083.
5. Raoul, C., C.E. Henderson, and B. Pettmann. 1999. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J. Cell Biol. 147:1049-1062.
6. Dauer, W., and S. Przedborski. 2003. Parkinson's disease: mechanisms and models. Neuron. 39:889-909.
7. Ferrer, I., R. Blanco, B. Cutillas, and S. Ambrosio. 2000. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol. Appl. Neurobiol. 26:424-433.
8. Mogi, M., M. Harada, T. Kondo, Y. Mizuno, H. Narabayashi, P. Riederer, and T. Nagatsu. 1996. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci. Lett. 220:195-198.
9. Hartmann, A., S. Hunot, and E.C. Hirsch. 1998. CD95 (APO-1/Fas) and Parkinson's disease. Ann. Neurol. 44:425-426.
10. Vila, M., and S. Przedborski. 2003. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4:365-375.
11. Gomez, C., J. Reiriz, M. Pique, J. Gil, I. Ferrer, and S. Ambrosio. 2001. Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells. J. Neurosci. Res. 63:421-428.
12. Adachi, M., R. Watanabe-Fukunaga, and S. Nagata. 1993. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. USA. 90:1756-1760.
13. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
14. Karray, S., C. Kress, S. Cuvellier, C. Hue-Beauvais, D. Damotte, C. Babinet, and M. Levi-Strauss. 2004. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J. Immunol. 172:2118-2125.
15. Petroske, E., G.E. Meredith, S. Callen, S. Totterdell, and Y.S. Lau. 2001. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience. 106:589-601.
16. Adachi, M., S. Suematsu, T. Kondo, J. Ogasawara, T. Tanaka, N. Yoshida, and S. Nagata. 1995. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 11:294-300.
17. Hayley, S., S.J. Crocker, P.D. Smith, T. Shree, V. Jackson-Lewis, S. Przedborski, M. Mount, R. Slack, H. Anisman, and D.S. Park. 2004. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 24:2045-2053.
18. Desbarats, J., R.B. Birge, M. Mimouni-Rongy, D.E. Weinstein, J.S. Palerme, and M.K. Newell. 2003. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5:118-125.
19. Ceccatelli, S., C. Tamm, E. Sleeper, and S. Orrenius. 2004. Neural stem cells and cell death. Toxicol. Lett. 149:59-66.
20. Anderson, C.N., and A.M. Tolkovsky. 1999. A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside. J. Neurosci. 19:664-673.
21. Shen, J. 2004. Protein kinases linked to the pathogenesis of Parkinson's disease. Neuron. 44:575-577.
22. van den Munckhof, P., K.C. Luk, L. Ste-Marie, J. Montgomery, P.J. Blanchet, A.F. Sadikot, and J. Drouin. 2003. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons. Development. 130:2535-2542.
23. Smeyne, M., and R.J. Smeyne. 2002. Method for culturing postnatal substantia nigra as an in vitro model of experimental Parkinson's disease. Brain Res. Brain Res. Protoc. 9:105-111.
24. Przedborski, S., V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and T.M. Dawson. 1996. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. USA. 93:4565-4571.
25. Hughes, A.J., Y. Ben-Shlomo, S.E. Daniel, and A.J. Lees. 1992. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 42:1142-1146.
26. Calne, D.B., B.J. Snow, and C. Lee. 1992. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32:S125-S127.